ASLN
Price:
$0.6
Market Cap:
$1.70M
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was fou...[Read more]
Industry
Biotechnology
IPO Date
2018-05-04
Stock Exchange
NASDAQ
Ticker
ASLN
According to ASLAN Pharmaceuticals Limited’s latest financial reports and current stock price. The company's current Enterprise Value is 9.97M. This represents a change of -95.62% compared to the average of 227.31M of the last 4 quarters.
The mean historical Enterprise Value of ASLAN Pharmaceuticals Limited over the last ten years is 545.45M. The current 9.97M Enterprise Value has changed 82.71% with respect to the historical average. Over the past ten years (40 quarters), ASLN's Enterprise Value was at its highest in in the June 2018 quarter at 2.07B. The Enterprise Value was at its lowest in in the December 2015 quarter at -18044708.00.
Average
545.45M
Median
524.08M
Minimum
58.96M
Maximum
1.12B
Discovering the peaks and valleys of ASLAN Pharmaceuticals Limited Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 707.09%
Maximum Annual Enterprise Value = 1.12B
Minimum Annual Increase = -65.38%
Minimum Annual Enterprise Value = 58.96M
Year | Enterprise Value | Change |
---|---|---|
2023 | 74.33M | -59.06% |
2022 | 181.58M | -65.38% |
2021 | 524.51M | -7.62% |
2020 | 567.77M | 8.43% |
2019 | 523.64M | -38.22% |
2018 | 847.56M | -21.23% |
2017 | 1.08B | -4.30% |
2016 | 1.12B | 136.28% |
2015 | 475.83M | 707.09% |
The current Enterprise Value of ASLAN Pharmaceuticals Limited (ASLN) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
260.14M
5-year avg
374.37M
10-year avg
545.45M
ASLAN Pharmaceuticals Limited’s Enterprise Value is less than Monte Rosa Therapeutics, Inc. (479.58M), less than NewAmsterdam Pharma Company N.V. (1.10B), less than Inventiva S.A. (230.21M), less than Cullinan Oncology, Inc. (815.34M), less than Compass Therapeutics, Inc. (210.95M), less than Structure Therapeutics Inc. (1.92B), greater than IO Biotech, Inc. (-21516335.00), less than Erasca, Inc. (696.19M), less than Lyra Therapeutics, Inc. (21.80M), less than Anebulo Pharmaceuticals, Inc. (45.92M), less than Mineralys Therapeutics, Inc. (603.95M), greater than AN2 Therapeutics, Inc. (5.76M), less than Aerovate Therapeutics, Inc. (48.31M), less than Adagene Inc. (59.89M), less than Acrivon Therapeutics, Inc. Common Stock (200.11M), less than Agios Pharmaceuticals, Inc. (2.35B), less than Assembly Biosciences, Inc. (85.72M), greater than Achilles Therapeutics plc (-48532901.00), less than CytomX Therapeutics, Inc. (46.62M), less than Instil Bio, Inc. (262.05M), greater than Neoleukin Therapeutics, Inc. (-6333315.00),
Company | Enterprise Value | Market cap |
---|---|---|
479.58M | $544.07M | |
1.10B | $1.63B | |
230.21M | $238.98M | |
815.34M | $927.63M | |
210.95M | $233.21M | |
1.92B | $2.29B | |
-21516335.00 | $77.08M | |
696.19M | $815.02M | |
21.80M | $16.95M | |
45.92M | $49.01M | |
603.95M | $671.81M | |
5.76M | $32.53M | |
48.31M | $78.69M | |
59.89M | $135.03M | |
200.11M | $241.89M | |
2.35B | $2.54B | |
85.72M | $103.18M | |
-48532901.00 | $42.12M | |
46.62M | $78.12M | |
262.05M | $183.22M | |
-6333315.00 | $8.20M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ASLAN Pharmaceuticals Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like ASLAN Pharmaceuticals Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is ASLAN Pharmaceuticals Limited's Enterprise Value?
What is the highest Enterprise Value for ASLAN Pharmaceuticals Limited (ASLN)?
What is the 3-year average Enterprise Value for ASLAN Pharmaceuticals Limited (ASLN)?
What is the 5-year average Enterprise Value for ASLAN Pharmaceuticals Limited (ASLN)?
How does the current Enterprise Value for ASLAN Pharmaceuticals Limited (ASLN) compare to its historical average?